Dx company Response Genetics draws huge GSK investment

Companion diagnostics continue to be all the rage. This time, Response Genetics is drawing increased attention from GlaxoSmithKline ($GSK). The drug giant already works with Response, which conducts companion diagnostic tests and other tasks for GSK's immunotherapy and cancer pipeline drug candidates, ShareCast reports. But now GSK has boosted its stake in Response, acquiring 5 million newly issued shares in the company. Story

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.